Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 92.5% | 138% | 262% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 42% | 30.8% | 36.3% | 35.5% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -65.8% | -231.5% | -837.7% | -1,164.7% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -84.5% | -254.4% | -735.5% | -1,272.9% |
| EPS Diluted | -0.024 | -0.037 | -0.17 | -0.095 |
| % Growth | 36.7% | 78.2% | -79.7% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |